Online citations, reference lists, and bibliographies.

The Resected Tumour Volume Of The Specimen As A Marker Of The Quality Of The Transurethral Resection In T1 Urinary Bladder Cancer

Jahnson Staffan, Olsson Hans
Published 2019 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Objective: To study the resected volume (RV) and the resected tumour volume (RTV) in the microscopic examination of the TUR specimen in relation to tumour size, clinical variables and outcome. Materials and methods: This prospectively performed population-based study included all patients in the Southeast Healthcare Region in Sweden with T1 UBC registered in the period 1992-2001, inclusive. RV, RTV and important clinic-pathological variables were studied. All patients had T1 tumours including detrusor muscle at the histopathological examination. Median values for RV and RTV were cut-off points for dichotomisation and 3 cm was the cut-off point for tumour size measured at TUR. Recurrence and progression were analysed using Kaplan-Meier curves with Log-rank test and Cox Proportional Hazards analysis. Results: Out of 211 patients we observed low RV in 112 (53%), low RTV in 113 (54%) and tumour size > 3 cm in 109 (52%). Patients with tumour size > 3 cm and low RV had shorter time to recurrence and progression compared to those with high RV (p = 0.006 and p = 0.087, respectively) and this was also the case when comparing patients with low RTV versus high RTV (p < 0.001 and p = 0.017, respectively). Conclusions: Patients with tumours > 3 cm and low RV or low RTV at TUR for T1 UBC are at higher risk for recurrence or progression, indicating an insufficient TUR. Extensive SLR is particularly important for these patients. RV and RTV might also be used as markers to monitor the quality of the TUR to improve treatment outcome.
This paper references
The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study.
Sten Holmäng (1997)
Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study
Maximilian C. Kriegmair (2017)
The value of a second transurethral resection in evaluating patients with bladder tumours.
Makram Miladi (2003)
Novel endoscopic diagnosis for bladder
SP Lerner (2015)
Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?
Paolo Capogrosso (2016)
Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial.
Rauf Taner Divrik (2010)
The Prognostic Value of T1 Bladder Cancer Substaging: A Single Institution Retrospective Study
Viktor Soukup (2014)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Marko Babjuk (2017)
Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link.
Karim Chamie (2015)
A new and highly prognostic system to discern T1 bladder cancer substage.
Bas W.G. van Rhijn (2012)
Novel endoscopic diagnosis for bladder cancer.
Seth P. Lerner (2015)
Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.
Patrik Andius (2007)
Second-look resection for primary stage T1 bladder cancer: a population-based study
Oliver Patschan (2017)
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Dieter Jocham (2005)
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
Angela Birnie (2011)
The value of a second transurethral resection for T1 bladder cancer.
Hartwig E Schwaibold (2006)
The impact of re-TUR on clinical outcomes in a large multicentre cohort of T1-HG/G3 patients treated with BCG
P Gontero (2016)
Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer.
Renzo Colombo (2018)
5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer.
Tammer Hemdan (2014)
: a process - outcomes link
P Capogrosso (2016)
Residual tumour in the marginal resection after a complete transurethral resection is associated with local recurrence in Ta/T1 urinary bladder cancer
Georg Jancke (2012)
The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer.
Mario Richterstetter (2012)
Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer.
Harry W. Herr (2011)
Dose, duration and strain of bacillus Calmette–Guerin in the treatment of nonmuscle invasive bladder cancer
Yongjun Quan (2017)
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Paolo Gontero (2015)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
Richard J. Sylvester (2002)
Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours
Hans Olsson (2013)

Semantic Scholar Logo Some data provided by SemanticScholar